Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Overview

To determine the appropriate dose and safety of a preventative dose of fondaparinux, an anticoagulant medication (blood thinner) in patients with kidney disease.

Full Title of Study: “Studies of Fondaparinux in Patients With Renal Dysfunction: PK Study of Fondaparinux in Outpatients With Renal Dysfunction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)

Detailed Description

This study will evaluate the PK of fondaparinux in patients who have renal insufficiency. Fondaparinux is cleared from the body mainly by the kidneys. Therefore in patients with kidney diseases, full doses of fondaparinux could cause bleeding problems. The correct dose of fondaparinux that should be used in patients with kidney disease is not known. The purpose of this research is to determine the PK and safety of a preventative dose (2.5mg subcutaneously every other day) of fondaparinux for patients with kidney disease.

Interventions

  • Drug: fondaparinux
    • injections of 2.5mg every other day for 4 weeks

Arms, Groups and Cohorts

  • Experimental: no arms/one group

Clinical Trial Outcome Measures

Primary Measures

  • PK parameters (half-life, area-under-the curve, and peak serum concentration)
    • Time Frame: after day 7 and after day 27

Secondary Measures

  • Anti-factor Xa levels and assessment for bleeding(complete blood count)
    • Time Frame: days 3, 13 and 19

Participating in This Clinical Trial

Inclusion Criteria

  • Outpatients in the Medicine and Nephrology clinics who are 18 years or older, – Outpatients in the Medicine and Nephrology clinics who have an estimated creatinine clearances between 20-30ml/min, – Outpatients in the Medicine and Nephrology clinics who are able to give consent will be included. Exclusion Criteria:

  • anticoagulation therapy for thrombosis or other indication – pregnant or breast-feeding – hypersensitivity to fondaparinux – subjects also will be excluded if there is concern for an increased risk of bleeding which includes the following: – known bleeding disorder (see Section 8. Hemostatic Assessment) – blood transfusion in the past 3 months – acute ulcer disease with past 3 months – platelet count < 120,000 mm3 – prolonged baseline prothrombin time (PT) or activated partial thromboplastin time (aPTT) above upper limit of normal laboratory range – major trauma or surgery within two weeks prior to enrollment – history of intracranial hemorrhage

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Duke University
  • Collaborator
    • GlaxoSmithKline
  • Overall Official(s)
    • Thomas L Ortel, PhD, Principal Investigator, Duke University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.